The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Guérin therapy. Dr. Necchi is an Associate Professor at Università Vita-Salute San Raffaele, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, and Vice President of the Global Society of Rare GU Tumors.
